Description
A previously healthy 54-year-old man presented with gradual vision loss, pain and swelling of the left eye, which started a month prior to admission. He was also experiencing night sweat, mild fever and noticed 10 lb weight loss since symptoms started. Physical examination showed inferior chemosis, lagophthalmos and mild proptosis of the left eye. Head CT showed a left-sided paranasal mass (figure 1), and subsequent MRI demonstrated a large lobulated infiltrative mass centred in the upper left nasal cavity with extension into the left orbits with resultant moderate proptosis and stretching of the optic nerve (figure 2A, B). CT of the chest, abdomen and pelvis revealed no evidence of lymphadenopathy or hepatosplenomegaly. Also, a bone marrow biopsy showed no lymphoid aggregate or interstitial increase of lymphocytes with normal flow cytometry results. A biopsy from the mass confirmed the diagnosis of stage IE extranodal diffuse large B-cell lymphoma (DLBCL) with strong expression of MUM1, CD5, BCL2, CMYC and BCL6, but negative CD3 and CD10 (figures 3A, B and 4A–G), suggesting an aggressive course of disease.1–3 Intravenous prednisone was initiated to minimise optic nerve compression and chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) was started alternating with intravenous methotrexate for central nervous system prophylaxis.4 5 The patient completed three courses of R-CHOP, with only partial recovery of visual acuity from 20/200 to 20/100 in a Snellen chart. Paranasal DLBCL is a very rare disease and results in optic nerve compression causing blindness. Prolonged optic nerve compression can lead to irreversible vision loss. Early diagnosis with imaging modalities is pivotal for the prognosis and steroid treatment is essential to minimise the complications from optic nerve compression.
Learning points.
Extranodal diffuse large B-cell lymphoma can present with paranasal mass and orbital infiltration in rare cases.
Prolonged optic nerve compression by mass can cause irreversible vision loss, and immediate steroid and chemotherapy are essential for a better clinical outcome.
Footnotes
Contributors: SY, JK and FA were involved in care of the patient, collecting data and all of the authors wrote up the case report. SY reviewed the literature and revised the manuscript.
Competing interests: None.
Patient consent: Obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.
References
- 1.Thieblemont C, Brière J. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? Blood 2013;121:2165–6 [DOI] [PubMed] [Google Scholar]
- 2.Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253–63 [DOI] [PubMed] [Google Scholar]
- 3.Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–82 [DOI] [PubMed] [Google Scholar]
- 4.Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23: 4117–26 [DOI] [PubMed] [Google Scholar]
- 5.Abramson JS, Hochberg M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010;116:4283–90 [DOI] [PubMed] [Google Scholar]